Psilocybin Race Tightens as Filings Collide But Durability Gap Caps Blockbuster Bet
Regulatory Approvals

Psilocybin Race Tightens as Filings Collide But Durability Gap Caps Blockbuster Bet

Published : 21 Nov 2026

At a Glance
IndicationTreatment-resistant depression
DrugCOMP360
CompanyCompass Pathways
Trial PhasePhase 3
CategoryRegulatory Milestone
Sub CategoryRegulatory Submission Filed
Therapeutic AreaNeuroscience
Competitor DrugPSIL201
Competitor CompanyUsona Institute
Competitor IndicationMajor Depressive Disorder
Regulatory AgencyFDA
Review DesignationCommissioner’s National Priority Voucher Program
Market Forecast (COMP360 Peak Sales)$1.9 billion
Estimated Drug List Price (COMP360)$34,000 per year
Dosing Frequency (COMP360)Two to four doses per year
Share Drop (Compass Pathways)30%
Follow-up Duration (COMP360 Phase 3 data)52 weeks

Psilocybin Race Intensifies as Usona Challenges Compass Pathways

The race for the first FDA-approved psilocybin treatment for depression has intensified, primarily between Compass Pathways' COMP360 for treatment-resistant depression and Usona Institute's PSIL201 for major depressive disorder. Usona's unconfirmed FDA filing for PSIL201, following its Phase 3 trial launch in March 2024 and securing a speedier review voucher, caused Compass Pathways' shares to drop by 30%. In response, Compass Pathways completed its own approval application for COMP360. Despite the new competition, analysts still project COMP360 to achieve blockbuster status, with RBC Capital Markets estimating peak sales of $1.9 billion in treatment-resistant depression alone.

  • Usona Institute's unexpected reported FDA filing for its psilocybin candidate, PSIL201, for major depressive disorder, has significantly altered the competitive landscape. This move, which followed Usona securing a speedier review voucher, led to a substantial 30% drop in Compass Pathways' shares and prompted Compass to accelerate the completion of its own FDA application for COMP360 for treatment-resistant depression.
  • Despite the new competition, analysts maintain that Compass Pathways' COMP360 is still projected to achieve blockbuster status, with RBC Capital Markets estimating peak sales of $1.9 billion in treatment-resistant depression. However, its commercial success hinges on navigating pricing (estimated at $34,000 per year for 2-4 doses), securing payer coverage, and ensuring patient access, especially given the complex administration requirements.
  • Securing payer coverage for COMP360 will require demonstrating value, likely for patients who have failed multiple generic antidepressants. Compass is emphasizing the drug's durability, citing 52-week Phase 3 data showing sustained reductions in depressive symptoms. The prospect of a treatment for this chronic disorder requiring only a few doses per year is seen as attractive to both patients and payers, potentially offsetting the high cost and in-clinic administration complexity.

Usona's Surprise Entry Reshapes the Psilocybin Approval Race

Second-generation antipsychotic augmentation has consolidated as a comparatively well-evidenced strategy, with refinement around agent selection and timing. Eleven randomized controlled trials including 5,300 participants evaluating brexpiprazole, cariprazine, aripiprazole, and quetiapine XR reported greater reductions in depressive symptoms compared with placebo, commonly measured by changes in the Montgomery-Åsberg Depression Rating Scale, with brexpiprazole augmentation yielding remission rates ranging from 22 to 31% and cariprazine augmentation showing rates of 22-32% across flexible-dose trials, early onset of action within 2-3 weeks, and discontinuation due to adverse events ranged from 0.4% to 8.6%. A total of 23 studies (N = 10679) with 24 augmentation agents included in Bayesian network meta-regression found aripiprazole 3 - 12 mg/d, brexpiprazole 1 - 3 mg/d, cariprazine 1.5 - 3 mg/d, olanzapine 6 - 12 mg/d and fluoxetine 25 - 50 mg/d combination, and quetiapine XR significantly effective with SMD ranged from -0.28 to -0.114, while a separate analysis of 56 RCTs (n=13616) found SGA augmentation associated with higher response than placebo (k=45; reported as OR with 95% CI: 1.53; 1.42-1.65; I²=0%), with only aripiprazole, quetiapine, brexpiprazole, and cariprazine demonstrating TSA-supported efficacy.

Glutamatergic approaches have extended from short-term efficacy to long-term maintenance data. In phase 3, open-label, long-term extension study, SUSTAIN-3, 1148 participants were enrolled, 458 at induction and 690 at optimization/maintenance, with mean (median) cumulative duration of maintenance esketamine treatment was 31.5 (37.7) months (totaling 2769 cumulative patient-years), mean [SD] change from the baseline to the endpoint of each phase: induction -12.8 [9.73]; optimization/maintenance +1.1 [9.93], with 35.6% and 46.1% of participants in remission (MADRS total score ≤12) at induction and optimization/maintenance endpoints, respectively, and no new safety signal was identified during long-term treatment (up to 4.5 years) using intermittent-dosed esketamine in conjunction with daily antidepressant. Re-analysis of IPD from 7 RCTs including 1505 patients found esketamine plus an antidepressant reduced MADRS scores at 4 weeks (mean difference (MD) = -2.94, 95% CI [-5.39 to -0.48]) and reduced relapse risk in a continuation trial (HR = 0.38 [0.26-0.57]), while in the Phase 3 Randomized Clinical Trial (GEMINI) in 327 patients randomized to dextromethorphan-bupropion (45 mg-105 mg tablet) or placebo, the least-squares mean change from baseline to week 6 in MADRS total score was -15.9 points in the dextromethorphan-bupropion group and -12.0 points in the placebo group (least-squares mean difference, -3.87; 95% confidence interval [CI], -1.39 to -6.36; P = .002), with remission achieved by 39.5% versus 17.3% and clinical response by 54.0% versus 34.0%.

Psychedelic and related rapid-acting agents have moved from exploratory open-label signals toward controlled trial programs. A synthetic psilocybin (COMP360) met its primary endpoint in two phase 3 trials in 2025-2026, while in a phase II, exploratory, international, fixed-dose, open-label study of a single 25 mg dose of psilocybin adjunct to a selective serotonin reuptake inhibitor in 19 participants with mean Baseline MADRS total score was 31.7 (SD = 5.77), mean change from Baseline in MADRS total score was -14.9 (95% CI, -20.7 to -9.2) at Week 3, and both response and remission were evident in 8 (42.1%) participants. For vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in 16 patients with treatment-resistant depression, the proportion of patients in remission (MADRS ≤10) at day 7 was 2/4 (50%) and 1/4 (25%) in the 12 mg and 18 mg groups of Phase 1, respectively, and 7/8 (87.5%) in the individualized dosing regimen group of Phase 2 with up to three increasing doses (6 mg, 12 mg, and 18 mg) within a single day, with mean MADRS change from baseline to day 7 was -21.0 (-65%) and -12.5 (-40%) for the 12 and 18 mg groups, respectively, and -24.4 (-76%) for the IDR.

Pricing, Payer Coverage, and Patient Access for Psychedelic Therapies

Current treatment approaches for treatment-resistant depression (TRD) face persistent efficacy, tolerability, and evidence gaps. Approximately 50% of depressed individuals fail to achieve remission with first-line antidepressant drugs and a third remain treatment-resistant, with higher risk of mortality including increased risk of suicide and substantial economic burden on health care systems.

  • High rates of non-response and heterogeneous definitions: Up to a third of elderly patients with major depressive disorder do not respond to a first course of treatment with an antidepressant, and resistance to antidepressant treatment has received a wide range of definitions with a lack of consensus on how to classify treatment resistance and failure to standardise clinical criteria in trials of new therapeutic approaches.

  • Limited and dated augmentation evidence base: Substantial efficacy of lithium augmentation has been demonstrated in more than 30 open-label studies and 10 placebo-controlled trials, with an odds ratio of 3.11 corresponding to a number-needed-to-treat (NNT) of 5 and a mean response rate of 41.2% (versus 14.4% in the placebo group), but most studies included augmentation of tricyclic antidepressants, which are not in widespread use anymore, with relatively small numbers of study participants and inconsistent results across studies possibly due to small sample sizes and inadequate statistical power.

  • Monitoring and tolerability burden: Lithium requires close therapeutic monitoring due to its narrow therapeutic range, with well-defined thresholds for efficacy and toxicity, in addition to its pharmacokinetic characteristics; tremors were significantly more prevalent among patients receiving lithium (p = .002), both age groups showed a significant eGFR decline over the course of treatment, and two AKIs were observed in the geriatric age group when serum lithium levels exceeded the therapeutic range of >0.8 mmol/L, while adjunctive therapy with atypical antipsychotics showed higher response rates but also had more withdrawals due to adverse events with ongoing concerns with longer term tolerability and safety.

  • Sparse long-term and special-population data: Evidence from continuation-phase studies is sparse but suggests that lithium augmentation should be maintained in the lithium-antidepressant combination for at least 1 year to prevent early relapses, there is a lack of controlled studies evaluating therapies for treatment-resistant depression in late-life depression, and for most add-on therapies placebo-controlled clinical trials with substantial numbers of patients have not been conducted.

  • Incomplete mechanistic and predictive understanding: The neural circuitry underlying the therapeutic effects of lithium augmentation is not yet fully understood, with dorsal raphe nucleus and CA3 regions of the dorsal hippocampus suggested as key nodes, and single studies have reported associations of better outcome with more severe depressive symptomatology, significant weight loss, psychomotor retardation, a history of more than three major depressive episodes and a family history of major depression.

Paving the Way for Future Psychedelic Medicines in TRD

Depression is increasingly conceptualized as a disorder of impaired synaptic plasticity and excitation-inhibition imbalance within corticolimbic circuits. Recent research has expanded beyond monoaminergic mechanisms to glutamatergic, GABAergic, serotonergic psychedelic, and other mechanism-driven targets, with rapid-acting antidepressants showing efficacy in treatment-resistant depression.

  • NMDA and metabotropic glutamate modulation: Non-competitive NMDA receptor antagonists including ketamine, memantine, dextromethorphan, and AZD6765, subunit (GluN2B/NR2B)-specific antagonists including CP-101,606/traxoprodil and MK-0657, and NMDA receptor glycine-site partial agonists including GLYX-13 and D-cycloserine, alongside metabotropic glutamate receptor modulators including AZD2066 and RO4917523/basimglurant, with AMPA agonists, AMPA receptor potentiators, mGluR2/3 negative allosteric modulators, and mGluR7 agonists as additional theoretical targets.

  • Neuroactive-steroid GABA-A positive allosteric modulation: Brexanolone, an intravenous GABA receptor PAM approved by the U.S. Food and Drug Administration for postpartum depression in patients 15 years and older, and zuranolone (SAGE-217), an oral neuroactive steroid PAM of synaptic and extrasynaptic GABA-A receptors investigated as a once-daily 14-day treatment course, plus PH10 acting on nasal chemosensory receptors, with zuranolone showing rapid antidepressant effects and preliminary evidence in major depression particularly in combination with antidepressants.

  • Serotonergic psychedelics via 5-HT2A receptor agonism: Psilocybin and its psychoactive metabolite psilocin, studied as innovative medication in treatment-resistant depression, provoke 5-HT2A-R-mediated augmentation of BDNF abundance, enhance synaptic plasticity through BDNF-TrkB signaling promoting spinogenesis and synaptogenesis, and increase neuronal complexity, synaptic protein expression, excitability, and synaptic network activity, with 5-HT receptor biased agonism explored to dissociate therapeutic effects from hallucinogenic actions.

  • Opioid, cholinergic, dopaminergic, and stress-axis mechanisms: Opioid system approaches including ALKS-5461 and kappa-opioid receptor antagonism investigated for anhedonia and depression, cholinergic targeting with scopolamine, corticotropin releasing factor receptor antagonists including CP-316,311, and dopaminergic enhancement strategies including bupropion and AXS-05, an oral combination of dextromethorphan and bupropion, supported by co-localization of NMDA and dopamine receptors and dopamine-induced phosphorylation of AMPAR.

  • Next-generation non-monoamine probes: Orexin, trace amine-associated receptor 1 (TAAR1), and members of the Q subfamily of voltage-gated potassium channels (KCNQ), plus Sigma-1 receptor agonists including Blarcamesine and Pridopidine, Neuropeptide Y-based approaches, Neurokinin 1 receptor antagonists, P2X7 purinergic receptor inhibition, sodium channel modulation, and orexin receptor antagonists including suvorexant and seltorexant under exploration beyond conventional monoaminergic approaches.

Frequently Asked Questions

What defines treatment-resistant depression and what are the current unmet needs in its management?
Treatment-resistant depression (TRD) is generally characterized as major depressive disorder that has not adequately responded to at least two distinct antidepressant treatments, administered at appropriate doses and durations. Patients with TRD often experience persistent and severe symptoms, significant functional impairment, and a reduced quality of life. Current unmet needs include therapies with novel mechanisms of action, improved efficacy, faster onset of action, and better tolerability profiles to achieve sustained remission.
How does COMP360's mechanism of action differ from conventional antidepressant therapies for TRD?
COMP360, a proprietary formulation of psilocybin, primarily acts as a potent agonist at the serotonin 5-HT2A receptor, leading to acute alterations in brain connectivity and perception. This mechanism contrasts with conventional antidepressants, which typically modulate monoamine neurotransmitter levels through reuptake inhibition or receptor antagonism. Its unique pharmacological profile is hypothesized to facilitate neuroplasticity and psychological processing, potentially offering a distinct therapeutic pathway for TRD.
What are the primary challenges in developing and delivering novel therapies for treatment-resistant depression?
Developing novel TRD therapies presents challenges in identifying distinct biological targets and demonstrating superior efficacy and durability over existing treatment options. Delivery challenges involve establishing appropriate care models, managing potential acute and long-term side effects, and ensuring equitable patient access. Regulatory pathways also require robust evidence for safety and long-term effectiveness in a complex and vulnerable patient population.
What are the key considerations for patient access and regulatory pathways for emerging TRD treatments like COMP360?
Patient access for novel TRD treatments involves navigating complex reimbursement policies, establishing specialized treatment centers, and training healthcare providers in new administration protocols. Regulatory pathways must address unique aspects of these therapies, such as the need for supervised administration and potential for abuse liability. Demonstrating a favorable benefit-risk profile and developing appropriate risk mitigation strategies are crucial for both regulatory approval and widespread adoption.

References

  1. [1] Jeon SW, Kim YK. The role of neuroinflammation and neurovascular dysfunction in major depressive disorder. Journal of inflammation research. 2018. 29773951
  2. [2] Pisanu C, Carvalho Silva R et al.. Effect of ketamine and esketamine on RNA expression and its relevance for depression: A systematic review. Pharmacological research. 2025 Sep. 40752781
  3. [3] Sugawara H, Sakamoto K et al.. Predictors of efficacy in lithium augmentation for treatment-resistant depression. Journal of affective disorders. 2010 Sep. 20089312
  4. [4] Zaki N, Chen LN et al.. Long-Term Safety and Maintenance of Response With Esketamine Nasal Spray in Participants With Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study. Focus (American Psychiatric Publishing). 2026 Apr. 42538888
  5. [5] Strickland JC, Johnson MW. Human behavioral pharmacology of psychedelics. Advances in pharmacology (San Diego, Calif.). 2022. 35341564
  6. [6] Machado-Vieira R, Henter ID et al.. New targets for rapid antidepressant action. Progress in neurobiology. 2017 May. 26724279
  7. [7] Hsu TW, Hsu CW et al.. Reappraising lithium, triiodothyronine and second-generation antipsychotic augmentation treatment for major depression: a systematic review and meta-analysis with bias-adjustment analyses. BMJ mental health. 2026 Jul 30. 42532626
  8. [8] Kéri S. [The use of psychedelics in psychiatry]. Orvosi hetilap. 2026 Sep 13. 42732542
  9. [9] Halaris A, Sohl E et al.. Treatment-Resistant Depression Revisited: A Glimmer of Hope. Journal of personalized medicine. 2021 Feb 23. 33672126
  10. [10] Serretti A. Rapid-acting NMDA and GABAergic Modulators in Mood Disorders: From Synaptic Mechanisms to Clinical Practice. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. 2025 Nov 30. 41139588
  11. [11] Berlin Viniegra JP. Management of Treatment-Resistant Depression: An Updated Narrative Review of Current and Emerging Treatments. Cureus. 2026 Apr. 42164210
  12. [12] Park D, Lee G et al.. The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine. Molecular psychiatry. 2025 Oct. 40624295
  13. [13] Thase ME. Have Effective Antidepressants Finally Arrived? Developments in Major Depressive Disorder Therapy. The Journal of clinical psychiatry. 2023 Aug 14. 37585245
  14. [14] Khalid R, Elbashir G et al.. Comparative Augmentative Efficacy of Second-Generation Antipsychotics in Adult Treatment-Resistant Depression: A Systematic Review. Cureus. 2026 May. 42367531
  15. [15] Swieczkowski D, Kwaśny A et al.. Lessons learned from the regulatory alignment in ketamine, esketamine and arketamine clinical trials: A cross-sectional analysis of protocols from ClinicalTrials.gov. Psychiatry research. 2025 Aug. 40440859
  16. [16] Inoue T, Abekawa T et al.. Long-term naturalistic follow-up of lithium augmentation: relevance to bipolarity. Journal of affective disorders. 2011 Mar. 20837361
  17. [17] Ji M, Feng J et al.. RETRACTED: Efficacy and safety of aripiprazole or bupropion augmentation and switching in patients with treatment-resistant depression or major depressive disorder: A systematic review and meta-analysis of randomized controlled trials. PloS one. 2024. 38669232
  18. [18] Cutler AJ, Mattingly GW et al.. Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder. Translational psychiatry. 2023 Jun 26. 37365161
  19. [19] Zaki N, Chen LN et al.. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2023 Jul. 37173512
  20. [20] Schindler F, Anghelescu IG. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. International clinical psychopharmacology. 2007 May. 17414745

Contact Us

📍

Address

350 Springfield Avenue,
Suite #200 Summit, NJ 07901

✉️

For General Inquiry

info@pienomial.com

Related Posts